ruthenium trichloride hydrate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 过渡金属盐
• 英文名称: ruthenium trichloride hydrate
• 英文别名: Ruthenium(3+);chloride;hydrate
• 化学式: 3Cl*H₂O*Ru
• 分子量: 225.444
• InChiKey: FXPJVFWZBOVFKC-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.82
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ruthenium trichloride hydrate 在 sodium periodate 、 sodium carbonate 作用下， 生成 benzyl (5R)-3-(9-fluorenyl)methoxycarbonyl-2,2-dioxo-1,2,3-oxathiazinane-5-carboxylate
  参考文献：
  名称：

  O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD

  摘要：

  发现通过将氨基酸衍生物与环化试剂反应可以生成环状磺胺酸酯。此外，还发现通过将环状磺胺酸酯与醇反应可以产生O-取代的丝氨酸衍生物。

  公开号：

  US20220017456A1
• 作为产物：
  描述：

  水合三氯化钌 以 乙醇 为溶剂， 生成 ruthenium trichloride hydrate
  参考文献：
  名称：

  Shorikov, Yu. S.; Vazhenin, I. S., Russian Journal of Inorganic Chemistry, 1989, vol. 34, p. 1185 - 1189

  摘要：

  DOI：
• 作为试剂：
  描述：

  1,3-双(二苯基膦)丙烷 、 碘甲烷 在 ruthenium trichloride hydrate 作用下， 以 甲醇 为溶剂， 生成 3-戊醇
  参考文献：
  名称：

  US2014/256992

  摘要：

  公开号：

文献信息

• 2-pyrrolidinones, pharmaceutical compositions containing these compounds
  申请人：Thomae; Karl

  公开号：US05455348A1

  公开（公告）日：1995-10-03

  The invention relates to cyclic imino derivatives of general formula B--X.sub.5 --X.sub.4 --X.sub.3 --X.sub.2 --X.sub.1 --A--Y--E(I) wherein A, B, E, X.sub.2 to X.sub.5 and Y are defined as in claim 1, the stereoisomers, tautomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, pharmaceutical compositions which contain these compounds and processes for preparing them.

  该发明涉及一般式B--X.sub.5 --X.sub.4 --X.sub.3 --X.sub.2 --X.sub.1 --A--Y--E(I)的环状亚胺衍生物，其中A、B、E、X.sub.2到X.sub.5和Y的定义如权利要求1中所述，其立体异构体、互变异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的药理特性，优选具有聚集抑制作用的药物组合物，包含这些化合物的制备方法。
• RUTHENIUM-DIAMINE COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
  申请人：Touge Taichiro

  公开号：US20140051871A1

  公开（公告）日：2014-02-20

  Provided is a ruthenium complex that is represented by general formula (1*) and is useful as an asymmetric reduction catalyst. (In the formula, * is an asymmetric carbon atom; R 1 is an arenesulfonyl group, and the like; R 2 and R 3 are a phenyl group, and the like; R 10 through R 14 are selected from a hydrogen atom, C 1-10 alkyl group, and the like, but R 10 through R 14 are not simultaneously hydrogen atoms; X is a halogen atom and the like; j and k are each either 0 or 1; and j+k is 0 or 2.)

  提供一个钌配合物，其由通式(1*)表示，可用作不对称还原催化剂。 (在公式中，*是不对称碳原子；R1是芳基磺酰基团等；R2和R3是苯基团等；R10至R14选自氢原子、C1-10烷基团等，但R10至R14不同时为氢原子；X是卤素原子等；j和k都是0或1；j+k为0或2。)
• CCK or gastrin modulating benzo \x9bb!\x9b1,4! diazepines derivatives
  申请人：Glaxo Wellcome Inc.

  公开号：US05859007A1

  公开（公告）日：1999-01-12

  Benzo\x9bb!\x9b1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.6 R.sup.7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R.sup.8 and R.sup.9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

  以下是您提供的化学公式和描述的中文翻译： 本专利涉及1,4-苯并二氮杂卓化合物，其分子式为(I)，其中R1选自C1-C6烷基、C3-C6环烷基、苯基或取代苯基；R2选自C3-C6烷基、C3-C6环烷基、C3-C6烯基、苄基、苯基C1-C3烷基或取代苯基；或NR1R2共同形成1,2,3,4-四氢喹啉或苯并氮卓环，且单独或同时以C1-6烷基、C1-6烷氧基或卤素取代基进行单、双或三取代；p为0或1的整数；q为0或1的整数；r为0或1的整数；t为0或1的整数，条件是当r为0时，t也为0；R3、R5和R6独立地为氢或C1-6烷基；R4为C1-6烷基或C1-6烯基；R7选自氢、C1-6烷基、C1-6环烷基、C1-6烯基、苯基、取代苯基、萘基、杂芳基、取代杂芳基、双环杂芳基或取代双环杂芳基；或NR6R7共同形成一个由1,2,3或4个N、S或O杂原子隔断的饱和的5,6或7元环，条件是任意两个O或S原子不得相互连接；m为0、1、2、3或4的整数；R8和R9选自多种取代基；Z为氢或卤素；本专利还包括新颖的中间体、用于治疗肥胖、胆囊淤滞、胰腺分泌障碍的药物组合物，以及用于治疗这些疾病的方法和制备公式(I)化合物的方法。
• Cyclic imino derivatives and pharmaceutical compositions containing them
  申请人：Karl Thomae GmbH

  公开号：US05541343A1

  公开（公告）日：1996-07-30

  The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。
• AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：US20140107109A1

  公开（公告）日：2014-04-17

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I： 其中化学式I中的变量A4、A5、A6、A8、R1、R2、R3、R7和n在此独立地被定义。该发明还提供了包含这些化合物的药物组合物，以及这些化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的对应用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II的化合物及其亚式化合物，中间体和用于制备化学式I-II化合物的有用过程和方法。